KRAS status predicts response to cetuximab in mCRC

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1641, 2008-01, pp. : 7-7

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cetuximab launched for mCRC, approved for SCCHN.

By  

Inpharma, Vol. 1, Iss. 1663, 2008-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite

Cetuximab extends survival in patients with mCRC

By  

Inpharma, Vol. 1, Iss. 1657, 2008-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Cetuximab first line in mCRC: benefits CRYSTAL clear

By  

Inpharma, Vol. 1, Iss. 1593, 2007-01 ,pp. : 13-14

Adis International

Access to resources Recommend Favorite

Cetuximab Inhibits Gastric Cancer Growth in vivo, Independent of KRAS Status

By  

Current Cancer Drug Targets, Vol. 14, Iss. 2, 2014-02 ,pp. : 217-224

Bentham Science Publishers

Access to resources Recommend Favorite

Bevacizumab gives a boost to chemotherapeutics in mCRC

By  

Inpharma, Vol. 1, Iss. 1603, 2007-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite